Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: The addition of a third immunosuppression agent to h-ATG + CyA did not result in any improvement. Antilymphocyte agents other than h-ATG have been investigated. A rabbit-ATG preparation, which was known to be more immunosuppressive than h-ATG, resulted in markedly inferior outcome in a large randomized study from the National Institutes of Health. These data seem to be confirmed in additional experiences with rabbit-ATG from other groups. Cyclophosphamide and alemtuzumab have been proven to be biologically active in small studies, but available data suggest inferior outcomes when compared with h-ATG. All these alternative agents result in a more pronounced lymphocyte depletion, suggesting that the actual mechanisms of action of immunosuppressive therapy in aplastic anemia are not fully understood. SUMMARY:
|
Authors | Antonio M Risitano |
Journal | Current opinion in hematology
(Curr Opin Hematol)
Vol. 19
Issue 1
Pg. 3-13
(Jan 2012)
ISSN: 1531-7048 [Electronic] United States |
PMID | 22143074
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antilymphocyte Serum
- Immunosuppressive Agents
- Cyclosporine
|
Topics |
- Anemia, Aplastic
(drug therapy)
- Animals
- Antilymphocyte Serum
(therapeutic use)
- Bone Marrow Diseases
- Bone Marrow Failure Disorders
- Cyclosporine
(therapeutic use)
- Hemoglobinuria, Paroxysmal
(drug therapy)
- Horses
- Humans
- Immunosuppression Therapy
(methods)
- Immunosuppressive Agents
(therapeutic use)
- Rabbits
|